Muss H B, Slavik M, Bundy B, Stehman F B, Creasman W T
Am J Clin Oncol. 1984 Jun;7(3):257-60. doi: 10.1097/00000421-198406000-00011.
Pala, 5G /M2 i.v. every 3 weeks was given to 32 evaluable patients with ovarian carcinoma (31 previously treated). No complete or partial responses were noted. Ten patients had stable disease for a median progression-free interval of 4.7+ months, while the remainder had progression of disease from the start of therapy. The major toxicity was dermatologic, and five patients had severe skin rash with desquamation or ulceration. There was no substantial hematologic or gastrointestinal toxicity. PALA displays no useful activity in previously-treated patients with ovarian cancer.
对32例可评估的卵巢癌患者（31例曾接受过治疗）每3周静脉注射5 - 氟尿嘧啶脱氧核苷（PALA）5G/M2。未观察到完全缓解或部分缓解。10例患者病情稳定，无进展生存期的中位数为4.7 +个月，其余患者从治疗开始就出现病情进展。主要毒性为皮肤毒性，5例患者出现严重皮疹伴脱屑或溃疡。未出现明显的血液学或胃肠道毒性。PALA对既往治疗过的卵巢癌患者无有效活性。
